Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Clinical Cancer Research|2025Cited by 12
Supplementary Table S1 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Unknown|2025Cited by 0
Supplementary Figure S3 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Unknown|2025Cited by 0
Data from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Matteo Morotti et al.|Unknown|2025Cited by 0
Supplementary Figure S1 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Unknown|2025Cited by 0